Health Care·Biotechnology·$2.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.23 | N/A | -7.98% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.23 | N/A | -7.98% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a cautious optimism about their ongoing projects. They acknowledged the challenges but emphasized their focus on future growth.
Management expressed a commitment to advancing their pipeline despite the loss.
They highlighted ongoing research efforts and potential future developments.
Celldex Therapeutics reported a loss that was slightly larger than expected, which typically raises concerns among investors. However, the stock reacted positively, gaining 0.16%, likely due to management's focus on future projects and ongoing research efforts. This suggests that investors may still have confidence in the company's long-term potential despite the current losses.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
HARTFORD INS GROUP I
Apr 29, 2013